Organ-on-Chip Market CAGR to be 25.6% by 2035, Due to the Increasing Need for Efficient Pre-clinical Testing Models | Roots Analysis

According to our latest market report "Organs-on-Chips Market" by Type of Product, Type of Organ, Type of Single Organ based Model, Type of Material of Construction, Purpose, Application Area, End User and Key Geographical Regions and Leading Players: Industry Trends and Global Forecasts, Till 2035", the global organ-on-chip market size is projected to reach USD 944 million by 2035 from USD 77 million in 2024, growing at a CAGR of 25.6% in the forecast period 2024-2035.

To request quote of this report, please visit: https://www.rootsanalysis.com/reports/organ-on-a-chip-market/request-quote.html

Organ-on-chips are microfluidic, in vitro, 3D cell culturing products that is used to replicate human tissues and diseases. Currently, organ-on-chips are primarily being used for pre-clinical studies and drug discovery as they stand out to be an excellent substitute to the use of animals for drug testing and research. Traditionally, animal testing was a crucial part of the drug development process, as it would justify the drug safety and its competence to deliver a therapeutic solution. However, there are several concerns over the experimental validity of animal-based research, such as less accurate observations, leading to harmful or ineffective reactions of drugs in humans, along with ethical concerns associated with the suffering caused to animals in the process. To remunerate the disadvantages of using animal test subjects, organ-on-chips are actively being utilized in pre-clinical research. Organ-on-chips involve the use of sophisticated cell culturing methodologies, thus generating reliable and specific biological data insights. Given the numerous applications of organ-on-chip technologies including drug screening, cancer research, stem cell research and disease modelling, organ-on-chips are anticipated to witness high adoption across pharmaceutical and biotech companies, followed by academic and research institutes.

Organ-on-chip Market Segments
Based on the type of product, the market is segmented into organ based models and disease based models.

1. The organ based model segment is likely to capture the largest share in the overall organ-on-chip market, accounting for 74% in share 2024.
2. The disease based model segment is anticipated to witness the highest market growth rate of 26.9%, annually, during the forecast period.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/organ-on-a-chip-market/request-sample.html

Based on the type of organ, the market is segmented into single organ based models and multi organ based models.

1. The single organ based model segment is likely to capture the largest share in the overall organ-on-chip market, accounting for 74% share in 2024.
2. The multi organ based model segment is anticipated to witness the market growth rate of 28.2%, annually, during the forecast period.

Based on the type of Single organ, the market is segmented into liver, lung, brain, heart, intestine, kidney and other organs based models.

1. The liver based model segment is likely to capture the largest share in the overall organ-on-chip market, accounting for over 25% share in 2024.
2. The brain based model segment is anticipated to witness a market growth rate of 25.6% annually, during the forecast period.

Based on the type of material of construction, the market is segmented into PDMS (polydimethylsiloxane), other polymers, glass and others.

1. The PDMS (polydimethylsiloxane) based model segment is likely to capture the largest share in the overall organ-on-chip market, accounting for over 45% share in 2024.
2. The other material based model segment is anticipated to witness the highest market growth rate of 27.2% annually, during the forecast period.

Based on purpose, the market is segmented into research and therapeutics.

1. The research segment is likely to capture the largest share in the overall organ-on-chip market, accounting for close to 55% share in 2024.
2. The therapeutic segment is anticipated to witness the highest market growth rate of 27.3%, annually, during the forecast period.

Based on the end user, the market is segmented into pharmaceutical and biotech companies, academic and research institutes, cosmetic industry players and other end users.

1. The pharmaceutical and biotechnology companies segment is likely to capture the largest share in the overall organ-on-chip market, accounting for close to 70% share in 2024.
2. The cosmetic industry segment is anticipated to witness the highest market growth rate of 27.5%, annually, during the forecast period.

Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa.

1. North America dominates the organ-on-chip market and accounts for the largest revenue share over 40% in 2024.
2. In Europe, the organ-on-chip market is anticipated to demonstrate a lucrative growth rate of 26.3%, annually, during the forecast period.

Organ-on-chip Market Regional Outlook
Based on the key geographical regions, the organ-on-chip market can be segmented into five major regions, including North America, Europe, Asia Pacific, Latin America and Middle East and North Africa. Led by the US, North America is anticipated to capture the majority share of the organ-on-chip market in 2024. Europe is accounted to be the fastest-growing segment of the market with the UK holding majority of market share. The growth of the organ-on-chip market in this region is primarily driven by escalated concerns for animal free testing, advancements in microfluidic technology, demand for therapeutic solutions to chronic disorders and increasing personalized therapeutics.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here: https://www.rootsanalysis.com/reports/organ-on-a-chip-market.html

Key Report Takeaways
1. More than 70 organ-on-chip technologies and models have been launched / approved or are currently under development; notably, the market landscape features the presence of both established players and new entrants
2. Presently, 25 players (established players as well as start-ups) claim to provide organ-on-chips and plates; more than 60% of these firms have been established post-2013
3. More than 600 patents related to organ-on-chip have been filed / granted by industry and non-industry stakeholders, indicating a growing intellectual capital in the domain
4. In the recent years, stakeholders have established strong brand positions to cater to the increasing demand for organ-on-chips, several players have emerged to introduce efficient, easy to use, and advanced products

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/organ-on-chip-market/request-sample.html

Organ-on-chip Market Key Players
Examples of key companies engaged in organ-on-chip market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AIM Biotech, Beonchip, BiomimX, CN Bio Innovations, Dynamic42, Emulate, Hesperos, InSphero, Mimetas, NETRI, React4life, SynVivo, TissUse and Xona Microfluidics.

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.